证券代码：603639 证券简称：海利尔 公告编号：2025-053 海利尔药业集团股份有限公司 关于公司第五届董事会第十一次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 海利尔药业集团股份有限公司(以下简称"公司")第五届董事会第十一次会议 于 2025 年 10 月 29 日以通讯表决的方式召开。会议通知于 2025 年 10 月 25 日以电 子邮件的方式发出，会议应到董事 9 名，实到董事 8 名，葛尧伦先生因个人原因未 出席会议。本次会议的召集和召开符合《中华人民共和国公司法》和《海利尔药业 集团股份有限公司章程》的有关规定，合法有效。 二、董事会会议审议情况 相关内容详见同日在上海证券交易所网站上披露的《海利尔药业集团股份有限 公司 2025 年第三季度报告》。 表决结果：同意票 8 票，反对票 0 票，弃权票 0 票。 本议案经公司董事会审计委员会审议通过后提交董事会审议。 2、审议通过《关于公司 2025 年三季度主要经营数据的议案》 相关内容详见同日在上海证券交易所网 ...

证券代码：603639 证券简称：海利尔 公告编号：2025-057 海利尔药业集团股份有限公司 关于 2025 年限制性股票激励计划内幕信息知情人 买卖公司股票情况的自查报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 3、本公司向中国证券登记结算有限责任公司就核查对象在自查期间买卖公 司股票的情况进行了查询确认，并由中国证券登记结算有限责任公司出具了《信 息披露义务人持股及股份变更查询证明》 《股东股份变更明细清单》。 二、核查对象买卖本公司股票的情况说明 根据中国证券登记结算有限责任公司出具的《信息披露义务人持股及股份变 更查询证明》及《股东股份变更明细清单》，在激励计划自查期间，所有核查对 象均不存在买卖公司股票的情况。 三、结论 综上所述，公司严格按照相关法律、法规及规范性文件的规定，建立了信息 披露及内幕信息管理的相关制度；公司本次股权激励计划策划、讨论过程中已按 照上述规定采取了相应保密措施，限定了接触内幕信息人员的范围，对接触到内 幕信息的相关公司人员及中介机构及时进行了登记；公司在本激励计划公告前， 未发 ...

北京市金杜（青岛）律师事务所（以下简称本所）接受海利尔药业集团股份 有限公司（以下简称公司）的委托，根据本法律意见书出具日前已经发生或存在 的事实和《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和 国证券法》（以下简称《证券法》）、《上市公司股东会规则》（以下简称《股 东会规则》）等中华人民共和国境内（以下简称中国境内，为本法律意见书之目 的，不包括中国香港特别行政区、中国澳门特别行政区和中国台湾省）现行有效 的法律、法规和规范性文件以及现行有效的《海利尔药业集团股份有限公司章程》 （以下简称《公司章程》）的有关规定，指派律师出席了公司于2025年10月29 日召开的2025年第一次临时股东会（以下简称本次股东会），并就本次股东会的 相关事项出具本法律意见书。 北京市金杜（青岛）律师事务所 关于海利尔药业集团股份有限公司 2025 年第一次临时股东会之法律意见书 致：海利尔药业集团股份有限公司 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1. 经公司 2024 年年度股东大会审议通过的《公司章程》； 2. 公司 2025 年 9 月 30 日披露于巨潮资讯网（http: ...

Financial Performance - The company's operating revenue for the third quarter was ¥781,925,704.44, a decrease of 3.19% compared to the same period last year[4] - The total profit for the quarter was ¥9,617,976.19, reflecting a significant decline of 73.19% year-over-year[4] - The net profit attributable to shareholders was ¥6,449,235.82, down 80.89% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses was ¥2,625,916.85, a decrease of 83.78% year-over-year[4] - The basic earnings per share for the quarter was ¥0.02, a decline of 79.18% compared to the same period last year[5] - The diluted earnings per share also stood at ¥0.02, down 79.22% year-over-year[5] - The weighted average return on equity was 0.24%, a decrease of 75.52% compared to the previous year[5] - Total operating revenue for the first three quarters of 2025 reached ¥3,390,781,300.03, an increase of 5.52% compared to ¥3,213,879,407.17 in the same period of 2024[19] - Total operating costs for the first three quarters of 2025 were ¥3,109,738,427.51, up from ¥2,940,226,911.15 in 2024, reflecting a year-on-year increase of 5.77%[19] - Net profit for the first three quarters of 2025 was ¥207,919,470.53, compared to ¥195,873,110.79 in 2024, representing an increase of 6.00%[20] - The company's earnings per share (EPS) for the first three quarters of 2025 was ¥0.61, up from ¥0.58 in the same period of 2024[21] - The company reported a tax expense of ¥40,966,815.03 for the first three quarters of 2025, compared to ¥30,683,337.52 in 2024, reflecting a significant increase of 33.47%[20] - Other comprehensive income after tax for the first three quarters of 2025 was ¥329,567.60, compared to a loss of ¥41,634.30 in the same period of 2024[21] Assets and Liabilities - Total assets at the end of the quarter were ¥6,976,700,595.97, an increase of 1.64% from the end of the previous year[5] - Shareholders' equity attributable to the parent company was ¥3,461,061,411.34, up 1.09% from the previous year[5] - The company's total current assets as of September 30, 2025, amount to ¥3,768,049,240.10, an increase from ¥3,674,877,593.55 at the end of 2024[15] - Accounts receivable increased to ¥1,197,512,726.74 from ¥873,216,631.07, indicating a growth of approximately 37.1%[15] - Total assets as of September 30, 2025, are ¥6,976,700,595.97, compared to ¥6,864,016,889.81 at the end of 2024[16] - Total current liabilities decreased to ¥3,060,793,285.72 from ¥3,226,389,446.91, a reduction of about 5.1%[16] - Total liabilities as of the reporting date were ¥3,515,639,184.63, compared to ¥3,440,203,095.45 in the previous year, indicating an increase of 2.19%[17] - Total equity attributable to shareholders reached ¥3,461,061,411.34, up from ¥3,423,813,794.36, marking a growth of 1.09%[17] - The total assets of the company amounted to ¥6,976,700,595.97, an increase from ¥6,864,016,889.81 in the previous year, indicating a growth of 1.63%[17] Cash Flow - The cash flow from operating activities for the year-to-date was ¥50,553,565.76, a decrease of 15.85% compared to the same period last year[5] - Net cash inflow from operating activities was $50,553,565.76, a decrease of 15.4% compared to $60,074,495.09 in the previous period[24] - Cash flow from operating activities for the first three quarters of 2025 was ¥2,186,919,372.76, slightly up from ¥2,182,606,535.03 in 2024[23] - Total cash inflow from investment activities was $925,045,880.27, up from $749,853,330.07, reflecting a growth of 23.4%[24] - Cash outflow from investment activities decreased to $983,685,621.52 from $1,222,399,759.59, indicating a reduction of 19.6%[24] - Net cash flow from financing activities was $269,911,765.11, down 48.8% from $526,477,899.42 in the previous period[25] - Total cash and cash equivalents at the end of the period reached $440,897,923.51, an increase of 54% compared to $286,238,262.92[25] - Cash received from borrowings amounted to $1,392,044,827.58, significantly higher than $832,341,820.55 previously, marking a rise of 67.5%[25] - Cash paid for the purchase of fixed assets and intangible assets was $132,714,333.27, down from $242,543,319.57, a decrease of 45.4%[24] - Cash received from investment income was $4,461,209.65, down from $10,469,153.74, a decline of 57.3%[24] - Cash received from other financing activities totaled $1,316,694,952.12, compared to $789,517,251.15, an increase of 67%[25] - The impact of exchange rate changes on cash and cash equivalents was a negative $1,129,619.32, contrasting with a positive impact of $679,126.84 previously[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,958[12] - The largest shareholder, Zhang Aiying, holds 127,253,000 shares, representing 37.43% of total shares[12] - The company has no significant changes in the top 10 shareholders or their shareholding status compared to the previous period[13] Strategic Developments - There are no new strategies or significant developments reported in the conference call[14]

Core Viewpoint - The pesticide sector experienced a significant rally in the afternoon, with multiple companies reaching their daily price limits [1] Company Performance - Changqing Co. and Yangnong Chemical both hit the daily limit up [1] - Liming Co., Runfeng Co., Hailier, Xin'an Co., and Guangxin Co. also saw increases in their stock prices [1]

证券代码：603639 证券简称：海利尔 公告编号：2025-052 海利尔药业集团股份有限公司 关于为全资子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 保 | 对 | 被担保人名称 | 青岛奥迪斯生物科技有限公司（以 下简称"奥迪斯生物"） | | | | --- | --- | --- | --- | --- | --- | | 担 | | 本次担保金额 | 15,000.00 万元 | | | | 象一 | | 实际为其提供的担保余额 | 28,421.13 万元 | | | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | | 本次担保是否有反担保 | □是 | 否 | □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额（万元） 0 | | | --- | --- | | 截至本公告日上市公司及其控股 | 333,100 | | 子公司对外担保总额（万元） | | | 对外担保 ...

Core Insights - The fungicide industry is experiencing rapid growth in China, driven by increasing public health awareness and environmental policies, with the market size projected to grow from 23.67 billion yuan in 2019 to 40.5 billion yuan by 2024, representing a compound annual growth rate (CAGR) of 11.34% [2][10] - The demand for environmentally friendly and biological fungicides is expected to rise significantly, particularly in the agricultural sector, which is the primary consumer market for fungicides [2][10] Industry Overview - Fungicides, also known as biocides, are chemical agents that effectively control or kill microorganisms such as bacteria, fungi, and algae [3] - The classification of fungicides can be based on application fields (industrial and agricultural), raw materials (inorganic, organic sulfur, organic phosphorus, etc.), usage methods (protective and therapeutic), and conduction characteristics (systemic and non-systemic) [3][8] Industry Policies - The Chinese fungicide industry is at a critical juncture influenced by policy changes and market transformations, with recent regulations aimed at promoting green and efficient fungicide production [5][7] - Key policies include the restriction of high-toxicity and high-residue pesticide production, as outlined in the "Industrial Structure Adjustment Guidance Catalog (2024 Edition)" [5][7] Industry Chain - The fungicide industry chain consists of upstream raw materials and production equipment, midstream research and manufacturing, and downstream applications in agriculture, forestry protection, urban greening, industrial corrosion prevention, and medical disinfection [8][10] Current Market Status - The global fungicide market is steadily expanding, with a projected market size of 19.704 billion USD in 2024, reflecting a year-on-year growth of 3.15% [10] - The growth is driven by the need for agricultural yield enhancement, public health protection, and food safety assurance, with expectations for the market to reach 22.942 billion USD by 2028 [10]

证券代码：603639 证券简称：海利尔 公告编号：2025-051 海利尔药业集团股份有限公司 董事会薪酬与考核委员会关于公司 2025 年限制性股票激励 计划首次授予激励对象名单的核查意见及公示情况说明 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （一）公司于 2025 年 9 月 30 日在上海证券交易所网站（www.sse.com.cn） 上披露了《海利尔药业集团股份有限公司 2025 年限制性股票激励计划（草案）》 （以下简称"《激励计划（草案）》"）及其摘要、《海利尔药业集团股份有限公司 2025 年限制性股票激励计划实施考核管理办法》以及《海利尔药业集团股份有 限公司 2025 年限制性股票激励计划激励对象名单》（以下简称"《激励对象名 单》"）等公告。 （二）公司对首次授予激励对象的内部公示情况 海利尔药业集团股份有限公司(以下简称"公司")于 2025 年 9 月 29 日召开 第五届董事会第十次会议审议通过了《关于公司 2025 年限制性股票激励计划（草 案）及其摘要的议案》 《关于公司 2025 年限 ...

海利尔药业集团股份有限公司 2025 年第一次临时股东会 会议材料 二〇二五年十月二十九日 海利尔药业集团股份有限公司 2025 年第一次临时股东会会议议程 一、会议召开的基本情况 二、会议议程 二、参会股东（或股东代理人）应严格按照本次会议通知所记载的会议登记方法 及时全面的办理会议登记手续及有关事宜。 三、出席大会的股东（或股东代理人）依法享有发言权、质询权、表决权等权利， 但需由公司统一安排发言和解答。 四、出席大会的股东（或股东代理人）要求在会议上发言，应当在出席会议登记 日或出席会议签到时，向公司登记。股东发言按持股数多少安排先后顺序。股东发言 由大会主持人指名后进行发言，发言时应先报告所持的股份份额。每位股东发言时间 一般不超过 5 分钟。股东不得无故中断大会议程要求发言。 五、股东（或股东代理人）就有关问题提出质询的，应当在出席会议登记日或出 席会议签到时向公司登记，安排公司董事或公司高管等相关人员回答每位股东的问 题，与本次股东会议题无关或将泄露公司商业秘密或有损公司、股东利益的质询，大 会主持人或相关负责人有权不予回答。 （一）会议类型和届次：2025 年第一次临时股东会 （二）会议召开时间 ...

Investment Rating - The industry investment rating is maintained as "Positive" [5] Core Viewpoints - The basic chemical industry is facing short-term challenges due to renewed US-China trade disputes, which have raised concerns about demand and led to a significant drop in international oil prices, with Brent crude oil prices falling by 4.8% [8] - Despite short-term pressures, the long-term outlook for the petrochemical industry remains positive, as high tariffs from trade disputes are unlikely to have a lasting impact, and domestic companies have gained valuable experience in navigating such challenges [8] - The green low-carbon sector is expected to become a new industry trend, with significant market potential for green methanol, bio-aviation fuel, and green polyester, which are anticipated to achieve rapid growth as they align with sustainable development goals [8] Summary by Sections Investment Recommendations and Targets - The report recommends buying shares of Wan Kai New Materials (301216) for its leading position in the green polyester industry. Other recommended stocks include: - Runfeng Co., Ltd. (301035) - Guoguang Co., Ltd. (002749) - Hailier (603639) - Sinopec (600028) - Hengli Petrochemical (600346) - Rongsheng Petrochemical (002493) - Wanhua Chemical (600309) - Huayi Group (600623) [3]